Physician profile
Marc Winnick
NPI 1730288838
$1,535.05
in general payments reported to CMS, 2019-2025
24 companies · $233 in 2025
The $233 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.61 · 2020: $176 · 2021: $143 · 2022: $640 · 2023: $106 · 2024: $213 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $552.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $169.68 | 2022-2023 | Clareon |
| Abbvie INC. | $164.39 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Dompe US, INC. | $153.28 | 2020-2025 | Oxervate |
| Beaver-Visitec International, INC. | $149.66 | 2022 | |
| Rxsight INC | $138.16 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $120.39 | 2022 | |
| Tearlab Corp | $104.69 | 2022 | |
| Astellas Pharma US INC | $94.55 | 2024-2025 | Izervay |
| Harrow Eye, LLC | $84.74 | 2025 | Vevye, Iheezo |
| Ocular Therapeutix, INC. | $50.09 | 2023-2024 | Dextenza |
| Tarsus Pharmaceuticals, INC. | $44.38 | 2024-2025 | Xdemvy |
| Alimera Sciences, INC. | $26.99 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $26.08 | 2025 | Eylea Hd, Eylea |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.61 | 2019 | |
| Amgen INC. | $21.63 | 2024 | Tepezza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $20.32 | 2020 | |
| New World Medical,INC. | $20.07 | 2022 | |
| Oyster Point Pharma, INC. | $19.64 | 2024 | Ryzumvi, Tyrvaya |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Rayner Intraocular Lenses Limited | $19.03 | 2022 | |
| Eyevance Pharmaceuticals LLC | $18.32 | 2021 | |
| Bausch & Lomb Americas INC. | $16.26 | 2025 | Xipere |
| Novartis Pharmaceuticals Corporation | $15.43 | 2020 | |
| Apellis Pharmaceuticals, INC. | $14.26 | 2025 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Winnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.